• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24133 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2024     National Institute for Health and Care Excellence (NICE) Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy. NICE technology appraisal guidance 962
2024     NIHR Health Technology Assessment programme Alitretinoin versus phototherapy as the first-line treatment in adults with severe chronic hand eczema: the ALPHA RCT
2024     NIHR Health and Social Care Delivery Program What happens between first symptoms and first acute exacerbation of COPD – observational study of routine data and patient survey
2024     Agency for Care Effectiveness (ACE) FEops HEARTguide for procedure planning in patients needing transcatheter left atrial appendage occlusion (LAAO) device
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, RF mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     National Institute for Health and Care Excellence (NICE) Sebelipase alfa for treating lysosomal acid lipase deficiency that is not Wolman disease (terminated appraisal). NICE technology appraisal guidance 961
2024     NIHR Health Technology Assessment programme The effect of two speech and language approaches on speech problems in people with Parkinson’s disease: the PD COMM RCT
2024     NIHR Health and Social Care Delivery Program Pathways to specialist community perinatal mental health services: a two-site longitudinal retrospective service evaluation
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor/tezacaftor/elexacaftor (cystic fibrosis, 2 to 5 years, F508del mutation, other/unknown mutation, heterozygous) – Benefit assessment according to §35a Social Code Book]
2024     National Institute for Health and Care Excellence (NICE) Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders (terminated appraisal). NICE technology appraisal guidance 960
2024     NIHR Health Technology Assessment programme Transperineal biopsy devices in people with suspected prostate cancer - a systematic review and economic evaluation
2024     Norwegian Institute of Public Health (NIPH) [Robot–assisted hysterectomy for benign conditions: A rapid health technology assessment]
2024     Institute for Clinical and Economic Review (ICER) Sotatercept for pulmonary arterial hypertension
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V]
2024     National Institute for Health and Care Excellence (NICE) Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis. NICE technology appraisal guidance 959
2024     NIHR Health Technology Assessment programme Preventive drug treatments for adults with chronic migraine: a systematic review with economic modelling
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: blood quantification of fludarabine by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS)]
2024     Institute for Clinical and Economic Review (ICER) KarXT for schizophrenia
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tebentafusp (uveal melanoma) – Benefit assessment according to §35a Social Code Book]
2024     National Institute for Health and Care Excellence (NICE) Ritlecitinib for treating severe alopecia areata in people 12 years and over. NICE technology appraisal guidance 958
2024     Institute for Clinical and Economic Review (ICER) Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Patisiran (hereditary transthyretin-mediated amyloidosis with polyneuropathy) – Benefit assessment according to §35a Social Code Book V]
2024     National Institute for Health and Care Excellence (NICE) Momelotinib for treating myelofibrosis-related splenomegaly or symptoms. NICE technology appraisal guidance 957
2024     NIHR Health Services and Delivery Research programme Consequences of how third sector organisations are commissioned in the NHS and local authorities in England: a mixed-methods study
2024     NIHR Health and Social Care Delivery Program Understanding and improving the quality of primary care for people in prison: a mixed-methods study
2024     Institute for Clinical and Economic Review (ICER) Midomafetamine-assisted psychotherapy for post-traumatic stress disorder
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trastuzumab deruxtecan (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2024     National Institute for Health and Care Excellence (NICE) Etrasimod for treating moderately to severely active ulcerative colitis in people aged 16 and over. NICE technology appraisal guidance 956
2024     Penn Medicine Center for Evidence-based Practice (CEP) Impact of workforce racial and ethnic diversity on patient health and healthcare outcomes
2024     NIHR Health and Social Care Delivery Program Challenges and guidance for implementing social distancing for COVID-19 in care homes: a mixed methods rapid review
2024     Institute for Clinical and Economic Review (ICER) Ensifentrine for the treatment of chronic obstructive pulmonary disease: effectiveness and value
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Early detection of vitamin B12 deficiency and other target diseases (homocystinuria, propionic acidaemia and methylmalonic acidaemia) in extended newborn screening (ENS)]
2024     National Institute for Health and Care Excellence (NICE) Dupilumab for treating moderate to severe prurigo nodularis. NICE technology appraisal guidance 955
2024     NIHR Health Technology Assessment programme MRI software and cognitive fusion biopsies in people with suspected prostate cancer: a systematic review, network meta-analysis and cost-effectiveness analysis
2024     NIHR Health and Social Care Delivery Program The effects of computerised decision support systems on nursing and allied health professional performance and patient outcomes: a systematic review and user contextualisation
2024     Institute for Clinical and Economic Review (ICER) Imetelstat for anemia in myelodysplastic syndrome: effectiveness and value
2024     NIHR Health Services and Delivery Research programme Practices of falls risk assessment and prevention in acute hospital settings: a realist investigation
2024     National Institute for Health and Care Excellence (NICE) Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 954
2024     NIHR Health Technology Assessment programme Antidepressants for pain management in adults with chronic pain: a network meta-analysis
2024     Health Sciences Institute in Aragon (IACS) [Portable external trigeminal nerve stimulator (eTNS) device for the treatment of migraine headaches]
2024     Institute for Clinical and Economic Review (ICER) Disease modifying therapies for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM)
2024     NIHR Health Technology Assessment programme Software with artificial intelligence-derived algorithms for analysing CT brain scans in people with a suspected acute stroke: a systematic review and cost-effectiveness analysis
2024     National Institute for Health and Care Excellence (NICE) Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema. NICE technology appraisal guidance 953
2024     NIHR Health Technology Assessment programme Specific phobias in children with moderate to severe intellectual disabilities: SPIRIT, an adaptation and feasibility study
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: prolotherapy's efficacy and safety in the treatment of chronic musculoskeletal pain]
2024     Institute for Clinical and Economic Review (ICER) Tabelecleucel for epstein-barr virus positive post-transplant lymphoproliferative disease: effectiveness and value
2024     NIHR Health Technology Assessment programme A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial)
2024     National Institute for Health and Care Excellence (NICE) Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations. NICE technology appraisal guidance 952
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Avapritinib (new therapeutic indication: indolent systemic mastocytosis (ISM))]
2024     Institute for Clinical and Economic Review (ICER) Managing the challenges of paying for gene therapy: strategies for market action and policy reform
2024     NIHR Health Technology Assessment programme Lower urinary tract symptoms in men: the TRIUMPH cluster RCT
2024     National Institute for Health and Care Excellence (NICE) Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer. NICE technology appraisal guidance 951
2024     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Momelotinib (myelofibrosis)]
2024     Institute for Clinical and Economic Review (ICER) Unsupported price increase report: unsupported price increases occurring in 2023
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Exposure therapy with virtual reality in adults with specific phobia]
2024     NIHR Health Technology Assessment programme Early switch from intravenous to oral antibiotic therapy in patients with cancer who have low-risk neutropenic sepsis: the EASI-SWITCH RCT
2024     National Institute for Health and Care Excellence (NICE) Nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over. NICE technology appraisal guidance 950
2024     Norwegian Medical Products Agency (NOMA) [Interferon gamma-1b for treatment of Friedreich’s ataxia: a health technology assessment without submitted documentation]
2024     Institute for Clinical and Economic Review (ICER) Assessment of barriers to fair access
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Vascular access systems for the creation of percutaneous arteriovenous hemodialysis fistula. Update]
2024     NIHR Health Technology Assessment programme Surgical versus non-surgical management of lateral compression type-1 pelvic fracture in adults 60 years and older: the L1FE RCT
2024     National Institute for Health and Care Excellence (NICE) Belumosudil for treating chronic graft-versus-host disease after 2 or more systemic treatments in people 12 years and over. NICE technology appraisal guidance 949
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Effectiveness and safety of deep brain stimulation in severe and treatment-resistant obsessive-compulsive disorder]
2024     National Institute for Health and Care Excellence (NICE) Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments. NICE technology appraisal guidance 948
2024     National Institute for Health and Care Excellence (NICE) Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments. NICE technology appraisal guidance 947
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Percutaneous treatment for moderate to severe mitral valve insufficiency]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: urethral discharge - diagnostic measures and pharmacological treatment]
2024     National Institute for Health and Care Excellence (NICE) Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer. NICE technology appraisal guidance 946
2024     National Institute for Health and Care Excellence (NICE) Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal). NICE technology appraisal guidance 945
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: hormone therapy for the management of the clinical manifestations of menopause]
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adults with treatment-resistant depression or posttraumatic stress disorder: a 2023 update
2024     National Institute for Health and Care Excellence (NICE) Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancer. NICE technology appraisal guidance 944
2024     Penn Medicine Center for Evidence-based Practice (CEP) Public health preparedness for mass gatherings
2024     NIHR Health Technology Assessment programme Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketamine for adults with substance use disorders
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Guides and standards: COVID-19 - optimal use of parmacological treatments]
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [Newsletter: access to innovations in health and social services - financing and decision-making]
2024     Scottish Health Technologies Group (SHTG) Outpatient biopsies (re-usable and disposable) equipment for suspicious laryngeal and pharyngeal lesions
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Ketorolac for renal colic
2024     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: overview – comparison, based on health profile, of the use of primary care medical services by persons registered with a family physician and those who are not]
2024     Swiss Federal Office of Public Health (FOPH) Trikafta® for the treatment of patients with cystic fibrosis: an exploratory economic evaluation
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Clinical and instrumental swallowing assessments for dysphagia
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Magnetic resonance neurography in peripheral neuropathy or plexopathy]
2024     Center for Drug Evaluation (CDE) [Health Technology Assessment Report : Opdivo (gastric cancer - GC)]
2024     Scottish Health Technologies Group (SHTG) Volatile capture technologies
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Timing of antibiotic therapy for neisseria gonorrhoeae infection
2024     NIHR Health Technology Assessment programme Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT
2024     Scottish Health Technologies Group (SHTG) Digital cancer prehabilitation
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Intra-articular hyaluronic acid for osteoarthritis of the hip, shoulder, and ankle
2024     NIHR Health Technology Assessment programme Low-dose titrated amitriptyline as second-line treatment for adults with irritable bowel syndrome in primary care: the ATLANTIS RCT
2024     Scottish Health Technologies Group (SHTG) Clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack (TIA) - SHTG Assessment
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Aerosol therapy with inhalers during mechanical ventilation
2024     National Institute for Health and Care Excellence (NICE) Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension. NICE technology appraisal guidance 1009
2024     Canadian Agency for Drugs and Technologies in Health (CADTH) Opioid-sparing effects of IV acetaminophen for patients undergoing surgery
2024     National Institute for Health and Care Excellence (NICE) Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments. NICE technology appraisal guidance 1008
2024     Penn Medicine Center for Evidence-based Practice (CEP) Indications for urinary catheterization in sedated patients
2024     NIHR Health Technology Assessment programme Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
2024     HTA South [Artificial intelligence in breast cancer screening with mammography]
2024     National Institute for Health and Care Excellence (NICE) Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. NICE technology appraisal guidance 1007
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Partially hydrolyzed formula to prevent cow’s milk allergy]